Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders
vivani | September 17, 2025
Read More
Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management
vivani | September 4, 2025
Read More
Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
vivani | August 20, 2025
Read More
Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results
vivani | August 13, 2025
Read More
Vivani Medical Appoints Anthony Baldor as Chief Financial Officer
vivani | June 11, 2025
Read More
Vivani Medical to Present at the 2025 BIO International Convention
vivani | June 10, 2025
Read More
Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders
vivani | May 29, 2025
Read More
Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results
vivani | May 13, 2025
Read More
Vivani Medical to Present at the American Association of Pharmaceutical Scientists’ “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop
vivani | May 7, 2025
Read More
Vivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & Company
vivani | April 16, 2025
Read More
Blog Navigation
Contact Us
To learn more about Vivani, and to learn more about our strategic focus on NPM-139 (semaglutide implant), please fill out this form.